OMER
NASDAQOmeros Corporation
News · 26 weeks43+140%
2026-03-012026-08-23
Mix2990d
- Insider16(55%)
- SEC Filings8(28%)
- Other3(10%)
- Earnings2(7%)
Latest news
25 items- INSIDERVP, Finance & CAO Borges David J. exercised 10,906 shares at a strike of $3.48 and sold $206,805 worth of shares (10,906 units at $18.96) as part of a pre-agreed trading plan (SEC Form 4)4 - OMEROS CORP (0001285819) (Issuer)
- INSIDERDirector Cable Thomas J. sold $276,772 worth of shares (15,000 units at $18.45) and exercised 15,000 shares at a strike of $2.96 (SEC Form 4)4 - OMEROS CORP (0001285819) (Issuer)
- INSIDERSEC Form 4 filed by Director Schocken Joseph L4 - OMEROS CORP (0001285819) (Issuer)
- INSIDERNew insider Schocken Joseph L claimed ownership of 528,082 shares (SEC Form 3)3 - OMEROS CORP (0001285819) (Issuer)
- INSIDERVP, Finance & CAO Borges David J. exercised 5,000 shares at a strike of $3.93 and sold $84,750 worth of shares (5,000 units at $16.95) as part of a pre-agreed trading plan (SEC Form 4)4 - OMEROS CORP (0001285819) (Issuer)
- SECSEC Form S-8 filed by Omeros CorporationS-8 - OMEROS CORP (0001285819) (Filer)
- SECOmeros Corporation filed SEC Form 8-K: Leadership Update8-K - OMEROS CORP (0001285819) (Filer)
- SECSEC Form 10-Q filed by Omeros Corporation10-Q - OMEROS CORP (0001285819) (Filer)
- SECOmeros Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - OMEROS CORP (0001285819) (Filer)
- PROmeros Corporation Reports Second Quarter 2026 Financial Results– Conference Call Today at 4:30 p.m. ET Omeros Corporation (NASDAQ:OMER) today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2026, which include: Second Quarter and Recent Highlights YARTEMLEA®, the first and only approved treatment for stem cell transplant-associated thrombotic microangiopathy (TA-TMA), an often-lethal complication of stem cell transplantation, generated gross revenues of $32.2 million in the second quarter of 2026, an increase of 190% from $11.1 million in the first quarter. Net revenue was $28.5 million, reflecting gross-to-net adjustments of approximately 11.5%, compared with $9.9 million and 11.0%
- PROmeros Corporation to Announce Second Quarter Financial Results on August 12, 2026Omeros Corporation (NASDAQ:OMER) today announced that it will issue its financial results for the second quarter of 2026 on Wednesday, August 12, 2026 after market close. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss recent developments and highlights as well as the Company’s financial results. Conference Call Details and Webcast Link Instructions To access the live webcast, please click here or visit the "Upcoming Events" section of the Investor Relations page of Omeros’ website. A replay of the call will be available for 90 days in the "Archived Events" section of the Investor Relations page of O
- PRCMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA®--Provides additional Medicare reimbursement to hospitals and supports patient access for eligible Medicare patients with TA-TMA-- Omeros Corporation (NASDAQ:OMER) today announced that the Centers for Medicare & Medicaid Services (CMS) has granted New Technology Add-On Payment (NTAP) status for YARTEMLEA® (narsoplimab-wuug) under the Fiscal Year (FY) 2027 Hospital Inpatient Prospective Payment System (IPPS) Final Rule. Beginning October 1, 2026, eligible hospitals treating Medicare patients with YARTEMLEA for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) will receive additional Medicare reimbursement. YARTEMLEA is the first and only FDA-approved treatme
- INSIDERSEC Form 4 filed by Chairman, CEO & President Demopulos Gregory A Md4 - OMEROS CORP (0001285819) (Issuer)
- INSIDERSEC Form 4 filed by VP, General Counsel Cancelmo Peter B4 - OMEROS CORP (0001285819) (Issuer)
- INSIDERSEC Form 4 filed by VP, Finance & CAO Borges David J.4 - OMEROS CORP (0001285819) (Issuer)
- SECOmeros Corporation filed SEC Form 8-K: Other Events8-K - OMEROS CORP (0001285819) (Filer)
- SECOmeros Corporation filed SEC Form 8-K: Other Events8-K - OMEROS CORP (0001285819) (Filer)
- PROmeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMAOmeros Corporation (NASDAQ:OMER) announced today an update on the review by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of the company’s marketing authorization application (MAA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Following an oral explanation meeting with the CHMP held this week, at which Omeros presented its position together with four international experts in hematopoietic cell transplantation, Omeros was informed that the CHMP has adopted a negative opinion on the MAA for narsoplimab in TA-TMA. Omeros intends to request re-examination of the CHMP
- SECOmeros Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - OMEROS CORP (0001285819) (Filer)
- INSIDERSEC Form 4 filed by Director Shah Rajiv4 - OMEROS CORP (0001285819) (Issuer)
- INSIDERSEC Form 4 filed by Director Perkinson Diana T.4 - OMEROS CORP (0001285819) (Issuer)
- INSIDERSEC Form 4 filed by Director Hood Leroy E. Md Phd4 - OMEROS CORP (0001285819) (Issuer)
- INSIDERSEC Form 4 filed by Director Hanish Arnold C4 - OMEROS CORP (0001285819) (Issuer)
- INSIDERSEC Form 4 filed by Director Demopulos Peter A Md4 - OMEROS CORP (0001285819) (Issuer)
- INSIDERSEC Form 4 filed by Director Cable Thomas J.4 - OMEROS CORP (0001285819) (Issuer)
OMER FAQ
7 questionsWhat does Omeros Corporation do?
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The company's clinical programs include Narsoplimab (OMS721/MASP-2) for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for...Where does OMER stock trade?
Omeros Corporation (OMER) is listed on NASDAQ.What sector and industry is OMER in?
Omeros Corporation operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Omeros Corporation go public?
Omeros Corporation (OMER) completed its IPO in 2009.What are analysts saying about OMER?
Omeros Corporation has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $900.00 price target on 2025-06-10.What companies are similar to OMER?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare OMER side-by-side with any of them on Quantisnow.How can I track OMER on Quantisnow?
Quantisnow aggregates Omeros Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow OMER to receive live email and push alerts on every new disclosure.